With three newly defined Strategic Business Units, a new Managing Director and an expanded product portfolio, the Life Science Division of Leica Microsystems is reinforcing its world market position in the life sciences. Dr. Stefan Traeger, the newly appointed Managing Director of Leica Microsystems CMS GmbH (Wetzlar and Mannheim), announced that in future the Life Science Division will be organized in three Strategic Business Units: Life Science Research, Clinical Imaging, and Nanotechnology. This will enable the division to provide its innovative systems and custom applications in a targeted manner to support the customer segments of biological research, microscopy in clinical environments, and sample preparation for electron microscopy.
With the purchase Liechtenstein-based Bal-Tec in February 2008 by Leica Microsystems, the Life Science Division has significantly enlarged the range products in can offer. New additions to the portfolio include equipment for sample preparation for scanning electron microscopy, which had been developed and marketed by Bal-Tec, and will perfectly complement Leica Microsystems’ own transmission electron microscopy equipment.
Dr. Stefan Traeger (40) joined Leica Microsystems at the beginning of the year and succeeded Dr. Martin Haase. He received his doctorate in physics and had previously worked in areas and positions of increasing management responsibility for the Zeiss Group. “By establishing these new Strategic Business Units, were are aligning our Life Science Division even more effectively on the market. This will enable us to respond more accurately, and thus even more quickly to the needs of our customers in the various segments,” explains Traeger.